Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir DF vs FTC+Tenofovir DF in Immune-Tolerant Chronic Hepatitis B
NCT00507507Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2007
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Tenofovir DF Monotherapy with FTC + Tenofovir DF Combination (2 arms). Primary endpoint: Percentage of Participants With HBV DNA < 400 Copies/mL at Week 192. Started Sep 2007; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00507507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00507507.